REYVOW® (lasmiditan): Absorption and Distribution

Additional Information Regarding Absorption and Distribution

Following oral administration, lasmiditan is rapidly absorbed with a median T_max of 1.8 hours.¹

In patients with migraine, the absorption or PK of lasmiditan was not different during a migraine attack versus during the interictal period.¹

The oral bioavailability over the clinical dose range of 50 mg to 200 mg is predicted to be 50% to 58%, based on the results from a population PK analysis.²

Lasmiditan may be taken with or without food as administration with meals was not associated with a clinically relevant effect on exposure to lasmiditan.¹

Coadministration of lasmiditan with a high-fat meal

• increased mean lasmiditan C_max and AUC values by 22% and 19%, respectively, and

• delayed the median T_max by 1 hour.¹

The human plasma protein binding of lasmiditan is

• approximately 55% to 60%, and

• independent of concentration between 15 and 500 ng/mL.¹

Enclosed Prescribing Information

REYVOW® (lasmiditan) tablets, for oral use, CV, Lilly

References

1. Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

AUC = area under the concentration

C_max = maximum observed drug concentration

PK = pharmacokinetics

T_max = time of maximum observed drug concentration